Abstract 104P
Background
Bladder-sparing treatment has emerged as an alternative choice for patients who are concerned about the life quality after radical cystectomy (RC). The optimal strategy for bladder-sparing treatment such as trimodal therapy (TMT) showed similar effects with RC. Since neoadjuvant immunotherapy has illuminated considerable response in MIBC, we aim to study whether neoadjuvant chemotherapy plus immunotherapy can improve the bladder-sparing rate in MIBC patients.
Methods
30 planned patients with MIBC (T2-4a N0-1 M0) received cisplatin 70mg/m2 or carboplatin AUC 4.5 on day 1 every 3 weeks (Q3W) plus gemcitabine 1000 mg/m2 on the 1st and 8th day of each 21-day cycle x 4 cycles. Tislelizumab 200mg was administered on the 14th day of each 21-day cycle at the 3rd and 4th cycles. CT and cystoscopy imaging were carried out to evaluate disease progression. After the 4th treatment, radical cystectomy, partial cystectomy or TURBT were perform in accordance with the disease status. For continuous bladder-sparing treatment, 2 additional cycles of tislelizumab were performed. Bladder-sparing rate was settled as the exploratory endpoint based on 2-years of follow-up and predictive biomarker will be analyzed.
Results
To date, 21 of 30 pts have been enrolled and 17 pts have completed the regimen. 2pts were excluded because of complicating with other disease (cerebral infraction or rectal cancer), and 2pts voluntarily quit due to intolerance of chemotherapeutic adverse effect (fatigue and gastrointestinal symptoms). 2pts showed partial response to the therapy and received RC after disease progression. 1pt have no response to the therapy and received palliative care as unsuitable for surgery. The remaining 10 of 17 pts successfully preserved their bladder by achieving pT0 (58.8%) after treatment. Among them, 3 pts have been followed up over 1 year and no relapse was observed.
Conclusions
These data support neoadjuvant chemotherapy plus immunotherapy as a feasible bladder-sparing choice for MIBC patients. Further completed follow-up data and biomarker analysis will accurately identify patients who are suitable for this therapy.
Clinical trial identification
ChiCTR2100050763.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
190P - Immune-related roles of B7H3 in glioblastoma
Presenter: Arnaud Simonet
Session: Poster Display
191P - Senolytic treatment remodels glioblastoma microenvironment
Presenter: Alexa Saliou
Session: Poster Display
192P - Analysis of Tumor-Associated Macrophages and Tumor-infiltrating Lymphocytes within the Tumor Microenvironment of Primary Tumors and Matched Brain Metastases
Presenter: Markus Kleinberger
Session: Poster Display
193P - Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibit anti-cancer immunity via CCL2
Presenter: Ronja Wieboldt
Session: Poster Display
194P - Achieving Reproducible Maturation Staging of Tertiary Lymphoid Structures: from Imaging Mass Cytometry Data to Pathology Applications
Presenter: Marion Le Rochais
Session: Poster Display
195P - IMMUcan - Toward a better understanding of the tumor microenvironment to inform precision oncology approaches.
Presenter: Marie Morfouace
Session: Poster Display
196P - Local glycan engineering induces systemic antitumor immune reactions via antigen cross-presentation
Presenter: Natalia Rodrigues Mantuano
Session: Poster Display
197P - Computational pathology pipeline enables quantification of intratumor heterogeneity and tumor-infiltrating lymphocyte score
Presenter: Daniel Tiezzi
Session: Poster Display
198P - Polarization of tumor-associated macrophages enhanced by 2-HP-_-cyclodextrin modified PLGA nanoparticles
Presenter: HAO YUAN
Session: Poster Display
199P - Scalable multiplexed image analysis across cancer types as part of the IMMUcan consortium
Presenter: Nils Eling
Session: Poster Display